Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease

P Saha, H Kathuria, MM Pandey - Journal of Controlled Release, 2023 - Elsevier
Parkinson's disease (PD) is the second leading neurodegenerative disease globally,
impacting the quality of life of millions of people. It is estimated that the treatment cost of PD …

Physiological and pathological factors affecting drug delivery to the brain by nanoparticles

Y Islam, AG Leach, J Smith, S Pluchino… - Advanced …, 2021 - Wiley Online Library
The prevalence of neurological/neurodegenerative diseases, such as Alzheimer's disease is
known to be increasing due to an aging population and is anticipated to further grow in the …

Importance of nanoparticles for the delivery of antiparkinsonian drugs

S Silva, AJ Almeida, N Vale - Pharmaceutics, 2021 - mdpi.com
Parkinson's disease (PD) affects around ten million people worldwide and is considered the
second most prevalent neurodegenerative disease after Alzheimer's disease. In addition …

Intranasal delivery of mucoadhesive nanocarriers: a viable option for Parkinson's disease treatment?

S Rehman, B Nabi, A Zafar, S Baboota… - Expert Opinion on Drug …, 2019 - Taylor & Francis
Introduction: Intranasal drug delivery is a largely unexplored, promising approach for the
treatment of various neurological disorders. However, due to the challenging constraints …

Development, characterization and pharmacokinetic evaluation of selegiline HCl loaded cubosomal thermoreversible mucoadhesive gel for nose to brain delivery

S Kakulade, D Kulkarni, K Moravkar, S Zambad… - Journal of Drug Delivery …, 2024 - Elsevier
Abstract Selegiline HCl (SGH) is MAO-B inhibitor with limited bioavailability due to extensive
hepatic metabolism. Thus, this work aims to formulate and evaluate SGH loaded intranasal …

Central composite design–based optimization, fabrication, and pharmacodynamic assessment of sulfasalazine-loaded lipoidal nanoparticle-based hydrogel for the …

R Mishra, N Jain, S Kaul, U Nagaich - Drug Delivery and Translational …, 2023 - Springer
Rheumatoid arthritis is a progressive, chronic, immunological, and inflammatory disorder
that is distinguished by joint inflammation, joint tenderness, and synovial joint destruction …

Olopatadine hydrochloride loaded Kollidon® SR nanoparticles for ocular delivery: Nanosuspension formulation and in vitro–in vivo evaluation

UM Güven, E Yenilmez - Journal of Drug Delivery Science and Technology, 2019 - Elsevier
Introduction Allergic eye diseases includes a spectrum of diseases, with each state being
characterized by a complicated immunopathology. In the present study, polymeric Kollidon® …

[PDF][PDF] Emerging promise of nanoparticle-based treatment for Parkinson's disease

MM Rahman, KS Ferdous… - Biointerface Res. Appl …, 2020 - biointerfaceresearch.com
Neurodegenerative disorders are consequences of the deterioration of cells and tissues with
a mature undesirable way of life. The degenerative disease like Parkinson's disease (PD) …

Potential applications of nanomedicine for treating Parkinson's disease

J Shankar, KM Geetha, B Wilson - Journal of Drug Delivery Science and …, 2021 - Elsevier
Parkinson's disease (PD) is an extrapyramidal, chronic progressive neurodegenerative
disorder. It affects approximately 5 million individuals globally, and by 2030, the prevalence …

Nanobiotechnology in neurodegenerative diseases

J Jampílek, K Kráľová, P Novák, M Novák - Nanobiotechnology in …, 2019 - Springer
Abstract “Neurodegenerative disease” is a term for a variety of disorders that primarily affect
neurons in the human brain and spinal cord. These diseases are presently incurable and …